In this free webinar, learn about achieving a robust, scalable and high-quality DNA supply in recombinant adeno-associated viral vector (rAAV) gene therapy manufacturing. Attendees will learn about a synthetically manufactured DNA to produce double stranded linear molecules with covalently closed ends. The featured speakers will discuss the many advantages of an enzymatic DNA technology over plasmid for the manufacturing of rAAV — quality of the material, elimination of bacterial sequences, amplification of difficult sequences including ITRs, lower amounts of DNA required for transfection and a scalable process to meet the DNA needs of any AAV manufacturing program. Attendees will learn about the use of this enzymatic DNA technology in Phase I/II.
TORONTO, March 16, 2023 /PRNewswire-PRWeb/ -- The gene therapy clinical pipeline continues to be in a growth phase, with over 2,000 therapies in development globally, with recombinant adeno-associated viral vectors (rAAV) as one of the most powerful tools for gene delivery to treat human disease, leading the way.
The manufacture of rAAV continues to be challenged to incorporate faster, safer, scalable and cheaper critical starting material and manufacturing processes to meet timelines and regulatory demands. dbDNA™1 (Doggybone™), a novel enzymatic DNA technology, is a good critical starting material for rAAV production that can support the demands in the rapidly evolving gene therapy field and addresses the current challenges faced in rAAV manufacture.
In this webinar, the featured speakers will present the TAAV-manufactured enzymatic DNA process and product, featuring the advantages of the technology, such as regulatory benefits of using a bacterial-free DNA vector, leading to a more efficient and robust production. The speakers will discuss the quality control and assurance system that enables TAAV to provide a high quality product that can support an efficient rAAV manufacturing process throughout all phases of development from preclinical to clinical.
Join the featured experts to learn more about achieving a robust, scalable and high-quality DNA supply in recombinant adeno-associated viral vector gene therapy manufacturing.
1 dbDNA™ technology is licensed from Touchlight UK.
Join experts from TAAV Biomanufacturing Solutions, Dr. Leticia Agúndez, R&D Senior Manager; and Lucía San Miguel, Quality Senior Manager, for the live webinar on Tuesday, March 28, 2023, at 3pm EDT (12pm PDT).
For more information, or to register for this event, visit rAAV Manufacturing — Enzymatic DNA for Achieving a Robust & High-Quality DNA Supply.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article